Q-omics provides the consensus-scored TTTY4B profile across patient tissues and cancer cell-line models. TTTY4B expression is associated with patient survival in 5 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TTTY4B is differentially expressed in 3, with the highest sampling consensus in KIRP. Additionally, TTTY4B RNA expression shows 1,322 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight SKCM, KIRP, and KIRC as cancer lineages where TTTY4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTTY4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTTY4B survival associations across molecular data types. TTTY4B RNA expression shows survival associations in the most cancer types (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTTY4B RNA expression–survival associations across cancer types. High TTTY4B expression shows unfavorable associations in SKCM, PAAD, KIRP and PRAD, but favorable associations in KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TTTY4B RNA expression.
This table summarizes TTTY4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TTTY4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTTY4B shows lower tumor expression in KIRP, KICH and KIRC. The KIRP box plot shows higher TTTY4B RNA expression in normal versus tumor tissue (log2 FC = −0.024, t-test p = .024).
This table shows molecular features associated with TTTY4B in patient tissues and cancer cell lines. In patient samples, TTTY4B shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
